Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

WeightWatchers' CEO said on Wednesday it planned to offer Novo Nordisk's much-anticipated Wegovy in pill form if it is ...

Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025.

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...

Novo Nordisk experienced a major board reshuffle at a recent shareholder meeting, led by the Novo Nordisk Foundation. This ...

Novo Nordisk's top shareholder forced through an overhaul of the Wegovy-maker's board at a shareholder meeting on Friday, ...

The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost ...

Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the ...

Rybelsus is now also indicated for cardiovascular risk reduction in adults with Type 2 diabetes who are at high risk, ...